UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

   [x] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange
       Act of 1934.

                 For the Quarterly Period Ended August 31, 2005

                                       or

   [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange
       Act of 1934.

    For the Transition Period From ____________________ To __________________

                        Commission File Number: 000-51007

                                NANOSENSORS, INC.
        (Exact name of small business issuer as specified in its charter)

<TABLE>
<CAPTION>
<S>                                                                     <C>
                           Nevada                                                      200452700
               (State or other jurisdiction of                            (I.R.S. Employer Identification No.)
               incorporation or organization)

                 1800 Wyatt Drive, Suite #2                                              95054
                       Santa Clara, CA
          (Address of principal executive offices)                                     (Zip Code)
</TABLE>

                    Issuer's telephone number: (408) 855-0051

                                       N/A
         (Former Name, Former Address and Former Fiscal Year, if Changes
                                Since Last Report


      Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ] *

      The revenues of the Registrant for the most recent fiscal year were: $ 0

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:

Common Stock, $0.001 par value 20,252,500 shares outstanding on October 17,
2005.


Transitional Small Business Disclosure Format (check one):        Yes [ ] No [X]

<PAGE>

<TABLE>
<CAPTION>
                                NANOSENSORS, INC.

                                      INDEX


                                                                                                                Page(s)
PART I.  FINANCIAL INFORMATION
<S>                                                                                                            <C>
         ITEM 1. CONDENSED FINANCIAL STATEMENTS................................................................... 3

Balance Sheets - August 31, 2005 (unaudited) and November 30, 2004................................................ 3

Statements of Operations for the Cumulative Period from December 23, 2003 (date
         of inception) to August 31, 2005. The Nine Months Ended August 31,
         2005, the Period From December 23, 2003 (date of inception) to August
         31, 2004 and The Three Months Ended August 31, 2005 and 2004 (unaudited)................................. 4

Statements of Cash Flows for the Cumulative Period from December 23, 2003 (date
         of inception) to August 31, 2005 The Nine Months Ended August 31, 2005
         and for the Period From December 23, 2003 (date of inception) to August 31, 2004 (unaudited)............. 5

Statement of Shareholders' Equity for the Period from December 23, 2003 (date of inception)
         to August 31, 2005 (unaudited)........................................................................... 7

Notes to Financial Statements .................................................................................... 8

         ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS............10

         ITEM 3. CONTROLS AND PROCEDURES..........................................................................15

PART II.  OTHER INFORMATION

         ITEM 1. LEGAL PROCEEDINGS................................................................................16

         ITEM 2. CHANGES IN SECURITIES............................................................................16

         ITEM 3. DEFAULTS UPON SENIOR SECURITIES..................................................................16

         ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.............................................16

         ITEM 5. OTHER INFORMATION................................................................................16

         ITEM 6. EXHIBITS.........................................................................................17

Signatures........................................................................................................18

Certifications
</TABLE>

                                      -2-

<PAGE>

PART I.  FINANCIAL INFORMATION
ITEM 1.  FINANCIAL STATEMENTS

                                NANOSENSORS, INC.
                          (A Development Stage Company)
                            CONDENSED BALANCE SHEETS
                            ------------------------
<TABLE>
<CAPTION>

                                                                                   August 31, 2005   November 30, 2004
                                                                                     (unaudited)         (audited)
                                                                                  -----------------  -----------------
                                   - ASSETS -
CURRENT ASSETS:
<S>                                                                               <C>                <C>
     Cash and cash equivalents                                                    $              -   $          13,558
     Inventory                                                                               16,072             16,072
                                                                                  -----------------  -----------------

TOTAL CURRENT ASSETS                                                                         16,072             29,630
                                                                                  -----------------  -----------------

PROPERTY AND EQUIPMENT - net of accumulated depreciation of $2,800 and $1,600,
   respectively                                                                               5,200              6,400
                                                                                  -----------------  -----------------

OTHER ASSETS:
     Licenses - net of amortization                                                          61,750             76,000
     Deposit                                                                                  3,000              3,000
                                                                                  -----------------  -----------------

                                                                                             64,750             79,000
                                                                                  -----------------  -----------------

TOTAL ASSETS                                                                      $          86,022  $         115,030
                                                                                  =================  =================

                    - LIABILITIES AND SHAREHOLDERS' DEFICIT -

CURRENT LIABILITIES:
     Cash overdraft                                                               $             545  $              -
     Accounts payable and accrued expenses                                                  249,597            178,535
     Accounts and advances payable - related parties                                        112,817             68,217
                                                                                  -----------------  -----------------

TOTAL CURRENT LIABILITIES                                                                   362,959            246,752
                                                                                  -----------------  -----------------

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' DEFICIT:
     Common stock, $.001 par value; 50,000,000 shares authorized; 20,252,500 and
        20,102,500 shares issued and outstanding in 2005 and 2004,
        respectively                                                                         20,253             20,103
     Additional paid-in capital                                                             619,524            589,674
     Deficit accumulated during the development stage                                      (916,714)          (741,499)
                                                                                  -----------------  -----------------
                                                                                           (276,937)          (131,722)
                                                                                  -----------------  -----------------
                                                                                  $          86,022  $         115,030
                                                                                  =================  =================
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                      -3-
<PAGE>


                                NANOSENSORS, INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                            ------------------------
                                   (Unaudited)

<TABLE>
<CAPTION>
                                      For the
                                     Cumulative                           For the
                                    Period from                         Period from
                                     Inception                           Inception
                                   (December 23,      Nine Months      (December 23,      Three Months      Three Months
                                  2003) to August    Ended August     2003) to August     Ended August      Ended August
                                     31, 2005          31, 2005           31, 2004          31, 2005          31, 2004
                                  ---------------   ---------------   ---------------   ---------------   --------------
<S>                               <C>               <C>               <C>               <C>               <C>
NET SALES                         $        11,688   $            -    $            -    $            -    $            -
                                  ---------------   ---------------   ---------------   ---------------   --------------
COSTS AND EXPENSES:
     General and administrative
       expense                            312,366            57,981           112,520            29,794            44,476
     Interest expense                      18,604                -              5,691                -                663
     Research and development             562,028           101,788           392,092                -             94,586
     Depreciation and
       amortization                        36,050            15,450            15,450             5,150             5,150
     Interest income                         (646)               (4)             (668)               -               (212)
                                  ----------------  ----------------  ----------------  ---------------   ----------------
TOTAL COSTS AND EXPENSES                  928,402           175,215           525,085            34,944           144,663
                                  ---------------   ---------------   ---------------   ---------------   ----------------

LOSS BEFORE INCOME TAXES                 (916,714)         (175,215)         (525,085)          (34,944)         (144,663)

     Income tax expense                        -                 -                 -                 -                 -
                                  ---------------   ---------------   ---------------   ---------------   ---------------

NET LOSS                          $      (916,714)  $      (175,215)  $      (525,085)  $       (34,944)  $      (144,663)

BASIC AND DILUTED NET LOSS PER
   SHARE                          $          (.05)  $          (.01)  $          (.03)  $          (.00)   $         (.01)
                                  ===============   ===============   ===============   ===============   ===============

WEIGHTED AVERAGE NUMBER OF
   COMMON SHARES OUTSTANDING           18,122,918        20,243,193        15,115,927        20,252,500        19,883,152
                                  ===============   ===============   ===============   ===============   ===============
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                      -4-

<PAGE>

                                NANOSENSORS, INC.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS
                            ------------------------
                                   (Unaudited)
                                                                     PAGE 1 OF 2

<TABLE>
<CAPTION>

                                       For the Cumulative Period                               For the Period from
                                            from Inception                                          Inception
                                         (December 23, 2003)         Nine Months Ended         (December 23, 2003)
                                          to August 31, 2005          August 31, 2005           to August 31, 2004
                                     -----------------------------   ------------------       ---------------------
<S>                                  <C>                            <C>                      <C>
INCREASE (DECREASE) IN CASH AND
  CASH EQUIVALENTS:
CASH FLOWS FROM OPERATING
  ACTIVITIES:
   Net loss                          $      (916,714)                $      (175,215)         $      (525,085)
    Adjustment to reconcile net
     loss to net cash utilized by
     operating activities:
      Depreciation and amortization           36,050                          15,450                   15,450
      Issuance common capital
       stock for expenses                     12,902                              -                     1,450
    Changes in assets and
     liabilities:
      Inventory                              (16,072)                             -                   (16,072)
      Prepaid expense and other
       current assets                             -                               -                   (64,583)
      Bank Overdraft                             545                             545                            -
      Accounts payable and
       accrued expenses                      479,314                         108,562                  349,255
                                     ---------------                 ---------------          ---------------
       Net cash (used) in
        operating activities                (403,975)                        (50,658)                (239,585)
                                     ----------------                ----------------         ----------------
CASH FLOWS FROM INVESTING
  ACTIVITIES
   Purchase of equipment                      (8,000)                             -                    (8,000)
   Purchase of license                       (90,000)                             -                   (90,000)
   Deposit                                    (3,000)                             -                    (3,000)
                                     ----------------                ---------------          ----------------
       Net cash (used) in
        investing activities                (101,000)                             -                  (101,000)
                                     ----------------                ---------------          ----------------
CASH FLOWS FROM FINANCING
  ACTIVITIES:
   Advances from officer                       7,100                           7,100                       -
   Proceeds from issuance of
    common stock                             497,875                          30,000                  379,325
                                     ---------------                 ---------------          ---------------
       Net cash provided by
        financing activities                 504,975                          37,100                  379,325
                                     ---------------                 ---------------          ---------------
NET INCREASE (DECREASE) IN CASH
  AND CASH EQUIVALENTS                            -                          (13,558)                  38,740
   Cash and cash equivalents at
    beginning of period                           -                           13,558                       -
                                     ---------------                 ---------------          ---------------
CASH AND CASH EQUIVALENTS AT END
  OF PERIOD                          $            -                  $            -           $        38,740
                                     ===============                 ===============          ===============
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                      -5-

<PAGE>



                                NANOSENSORS, INC.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS
                                   (Unaudited)

                                                                     PAGE 2 OF 2

<TABLE>
<CAPTION>
<S>                                        <C>                     <C>                     <C>
NON CASH FLOWS FROM OPERATING ACTIVITIES:
       Issuance of 11,635,000 common
         shares for services               $        14,352         $            -          $         6,450
                                           ===============         ===============         ===============
SUPPLEMENTAL CASH FLOW INFORMATION:
CASH PAID DURING THE PERIOD FOR:
       Interest                            $        18,604         $            -          $         5,028
                                           ===============         ===============         ===============
</TABLE>






























   The accompanying notes are an integral part of these financial statements.

                                      -6-

<PAGE>

                                NANOSENSORS, INC.
                          (A Development Stage Company)
                        STATEMENT OF SHAREHOLDERS' EQUITY
                        ---------------------------------
                                   (Unaudited)
<TABLE>
<CAPTION>

                                                                           Common Shares              Additional
                                                                 ----------------------------------     Paid-in
                                                                      Shares             Amount         Capital
                                                                 ---------------    ---------------   ---------------
<S>                                                            <C>                 <C>                <C>
BALANCE AT DECEMBER 23, 2003, INCEPTION                                             $            -    $            -

   Issuance of common stock for license at $.001                       5,000,000              5,000                -

   Issuance of common stock for services and expenses at $.001        11,450,000             11,450                -

   Issuance of common stock for cash at $.05                               9,500                 10               465

   Issuance of common stock for cash at $.20 - net of issuance
     costs                                                             2,750,000              2,750           460,250

   Issuance of common stock for note receivable - at $.05 -
     paid in June 2004                                                    88,000                 88             4,312

   Issuance of common stock for payment of debt at $.20                  620,000                620           123,380

   Issuance of common stock for expenses at $.0078                       185,000                185             1,267

   Net loss                                                                   -                  -                 -
                                                                 ---------------    ---------------   ---------------

BALANCE AS OF NOVEMBER 30, 2004                                       20,102,500             20,103           589,674

   Issuance of 150,000 shares for cash                                   150,000                150            29,850

   Net loss (Unaudited)                                                       -                  -                 -
                                                                 ---------------    ---------------   ---------------

BALANCE AS OF AUGUST 31, 2005 (UNAUDITED)                             20,252,500    $        20,253   $       619,524
                                                                 ===============    ===============   ===============
</TABLE>

<TABLE>
<CAPTION>

                                                                  Deficit Accumulated
                                                                      During the
                                                                   Development Stage            Total
                                                                  -------------------     ----------------
<S>                                                              <C>                     <C>
BALANCE AT DECEMBER 23, 2003, INCEPTION                            $            -          $            -

   Issuance of common stock for license at $.001                                -                    5,000

   Issuance of common stock for services and expenses at $.001                  -                   11,450

   Issuance of common stock for cash at $.05                                    -                      475

   Issuance of common stock for cash at $.20 - net of issuance
     costs                                                                      -                  463,000

   Issuance of common stock for note receivable - at $.05 -
     paid in June 2004                                                          -                    4,400

   Issuance of common stock for payment of debt at $.20                         -                  124,000

   Issuance of common stock for expenses at $.0078                              -                    1,452

   Net loss                                                               (741,499)               (741,499)
                                                                   ----------------        ----------------

BALANCE AS OF NOVEMBER 30, 2004                                           (741,499)               (131,722)

   Issuance of 150,000 shares for cash                                          -                   30,000

   Net loss (Unaudited)                                                   (175,215)               (175,215)
                                                                   ----------------        ----------------

BALANCE AS OF AUGUST 31, 2005 (UNAUDITED)                          $      (916,714)        $      (276,937)
                                                                   ================        ================
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                      -7-

<PAGE>

                                NANOSENSORS, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                 AUGUST 31, 2005


NOTE 1  -  DESCRIPTION OF COMPANY/BASIS OF PRESENTATION:

           NanoSensors, Inc. (the "Company"), was incorporated under the laws
           of the state of Nevada on December 23, 2003 with authorized common
           stock of 50,000,000 shares at $.001 par value.

           The Company was organized for the purpose of the development and
           marketing of sensors to detect explosives, chemicals, and biological
           agents. The Company continues to report as a development stage
           company pursuant to SFAS No. 7 since it has not commenced any
           significant operations and generated any revenues.

           In the opinion of management, the accompanying unaudited interim
           condensed financial statements of NanoSensors, Inc. contain all
           adjustments necessary to present fairly the Company's financial
           position as of August 31, 2005 and November 30, 2004 and the results
           of its operations and cash flows for the cumulative period from
           inception (December 23, 2003) to August 31, 2005, the nine months
           ended August 31, 2005, the period from inception (December 23, 2003)
           to August 31, 2004 and the three months ended August 31, 2005 and
           2004. The results of operations for the nine months ended August 31,
           2005 are not necessarily indicative of the results to be expected for
           the full year.

           The accounting policies followed by the Company are set forth in
           Note 2 to the Company's financial statements included in its
           Annual Report on Form 10-KSB for the year ended November 30, 2004,
           which is incorporated herein by reference. Specific reference is
           made to this report for a description of the Company's securities
           and the notes to financial statements included therein. The
           accompanying unaudited interim condensed financial statements have
           been prepared in accordance with accounting principles generally
           accepted in the United States of America for interim financial
           information and with the instructions to Form 10-QSB. Accordingly,
           they do not include all of the information and footnotes required
           by accounting principles generally accepted in the United States
           of America.

NOTE 2  -  GOING CONCERN:

           The Company will need additional working capital for its future
           planned activity and for payment of its current liabilities, which
           raises substantial doubt about its ability to continue as a going
           concern. Continuation of the Company as a going concern is
           dependent upon sales, the exercising of outstanding warrants, and
           the proceeds from a contemplated common stock offering. The net
           proceeds from these sources are expected to meet the Company's
           needs for the coming year.

           If the Company does not obtain additional capital from these
           sources, other funds will be needed in order to produce other
           products currently in development. If additional funds are
           required earlier than anticipated there can be no assurance that
           we will be able to obtain such funds from financial institutions,
           government funding, the exercise of the warrants, and otherwise,
           on a basis deemed acceptable.

                                      -8-
<PAGE>

NOTE 3  -  PURCHASE OF LICENSE:

           On December 11, 2003, the Company purchased a worldwide,
           perpetual, exclusive, marketing license from Axiom Corp and Matt
           Zuckerman for the use of, and further development of, sensor
           technology for detecting explosives, chemicals and biological
           agents. The terms of the purchase included a one time licensing
           fee of $90,000 and the issuance of 5,000,000 common shares of
           stock, with an estimated value of $5,000, and a consulting
           agreement, which provides for a monthly fee of $8,500, as revised
           on May 1, 2004, to be paid for the further development of the
           sensors. During the term of the consulting agreement all
           technology for detecting explosives, chemicals, and biological
           agents, developed and ready for patent application will be
           assigned to the Company.

           The license was determined by management to have a useful life of
           five years and is being amortized on the straight line method.

NOTE 4  -  SHAREHOLDERS' EQUITY:

           During the nine month period ended August 31, 2005, the Company
           received $30,000 from the sale of 150,000 shares of its common stock.

NOTE 5  -  RELATED PARTY TRANSACTIONS:

           During the period ended August 31, 2005, the President and Chief
           Executive Officer of the Company made advances to the Company in the
           aggregate amount of $7,100. These advances are non-interest bearing
           and are payable upon demand. At August 31, 2005, accounts and
           advances payable to related parties also include consulting fees
           payable.














                                      -9-

<PAGE>

      Unless the context requires otherwise, references in this Quarterly Report
to "NanoSensors", "the Company", "we", "our" and "us" refer to NanoSensors, Inc.

                     FACTORS THAT MAY AFFECT FUTURE RESULTS

      This report contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
include, but are not limited to, statements concerning our plans to continue
development of our current product candidates; address certain markets; engage
third-party manufacturers; and evaluate additional product candidates for
subsequent commercial development. In some cases, these statements may be
identified by terminology such as "may," `will," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential," or "continue," or
the negative of such terms and other comparable terminology. Although we believe
that the expectations reflected in the forward-looking statements contained
herein are reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. These statements involve known and unknown risks
and uncertainties that may cause our or our industry's results, levels of
activity, performance or achievements to be materially different from those
expressed or implied by forward-looking statements. Factors that may cause or
contribute to such differences include, among other things, those discussed
under the captions "Business," "Risk Factors" and "Management's Discussion and
Analysis-Plan of Operation" in our reports and registration statements filed
with the Securities and Exchange Commission.

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

      Management's Discussion and Analysis of Financial Condition and Results of
Operations should be read together with our financial statements and related
notes included elsewhere in this Quarterly Report on Form 10-QSB. This Quarterly
Report on Form 10-QSB, including the following discussion, contains trend
analysis and other forward-looking statements within the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Any statements in this
Quarterly Report on Form 10-QSB that are not statements of historical facts are
forward-looking statements. These forward-looking statements are based on a
number of assumptions and involve risks and uncertainties. Actual results may
differ materially from those set forth in such forward-looking statements as a
result of factors set forth elsewhere in this Quarterly Report on Form 10-QSB.

Critical Accounting Policies

      In December 2001, the Securities and Exchange Commission requested that
all registrants discuss their "critical accounting policies" in management's
discussion and analysis of financial condition and results of operations. The
SEC indicated that a "critical accounting policy" is one that is both important
to the portrayal of the company's financial condition and results and that
requires management's most difficult, subjective or complex judgments. Such
judgments are often the result of a need to make estimates about the effect of
matters that are inherently uncertain. While NanoSensors' significant accounting
policies are more fully described in Note 2 to its financial statements
contained in its Annual Report of Form 10-KSB for November 30, 2004, NanoSensors
currently believes the following accounting policies to be critical:

Development Stage Company

      NanoSensors is considered to be in the development stage as defined in
Statement of Financial Accounting Standards (SFAS) No. 7, "Accounting and
Reporting by Development Stage Enterprises." NanoSensors has devoted
substantially all of its efforts to business planning, research and development,
recruiting management and technical staff, acquiring operating assets and
raising capital.

                                      -10-
<PAGE>

Cash and Cash Equivalents

      NanoSensors considers all highly liquid debt instruments and other
short-term investments with an initial maturity of less than three months to be
cash equivalents.

      At times NanoSensors maintains cash and cash equivalent balances at
financial institutions which are not insured by the Federal Deposit Insurance
Corporation for amounts over $100,000, but are otherwise in financial
institutions of high credit quality.

Fixed Assets

      Fixed assets are stated at cost. Depreciation is computed using the
straight-line method over the estimated useful lives of the assets; three years
for computer software and equipment and five and seven years for office
furniture and equipment. Property and equipment held under capital leases and
leasehold improvements are amortized over the shorter of the lease term or the
estimated useful life of the related asset. When fixed assets are retired or
otherwise disposed of, the cost and related accumulated depreciation are removed
from the accounts and the resulting gain or loss is included in operations.

Intellectual Property Assets

      NanoSensors owns no issued and no pending U.S. and Foreign patents. Under
present accounting principles generally accepted in the United States of
America, and FASB 142, the value of patents, if any, will not be reflected on
its condensed balance sheet. See also Note 3 to the notes to financial
statements.

Internal Use Software Costs

      Internal use software and web site development costs are capitalized in
accordance with Statement of Position (SOP) No. 98-1, "Accounting for the Costs
of Computer Software Developed or Obtained for Internal Use," and Emerging
Issues Task Force (EITF) Issue No. 00-02, "Accounting for Web Site Development
Costs." Qualifying costs incurred during the application development stage,
which consist primarily of outside services and NanoSensors' consultants, are
capitalized and amortized over the estimated useful life of the asset. All other
costs are expensed as incurred. All costs for internal use software for the
period ended April 30, 2004, have been expensed as research and development
expense.

Start-up Costs

      In accordance with the American Institute of Certified Public Accountants
Statement of Position 98-5, "Reporting on the Costs of Start-up Activities",
NanoSensors expenses all costs incurred in connection with the start-up and
organization of NanoSensors.

Research and Development

      Research and development costs are related primarily to NanoSensors
developing early prototypes. Research and development costs are expensed as
incurred.

Income Taxes

      An income tax benefit is computed on the pretax loss based on the current
tax law. Deferred income taxes are recognized for the tax consequences in future
years of differences between the tax basis of assets and liabilities and their
financial reporting amounts at each year-end based on enacted tax laws and
statutory tax rates. No benefit is reflected for the period ended August 31,
2005. Deferred tax assets due to operating losses aggregated approximately
$365,000 at August 31, 2005. We have established a 100% valuation allowance
against this asset until it is more likely than not to be realized.

                                      -11-
<PAGE>

Advertising

      Advertising and marketing costs will be expensed as incurred. No
advertising and marketing costs were incurred for the period ended August 31,
2005.

Earnings (Loss) Per Share of Common Stock

      Basic net income (loss) per common share is computed using the weighted
average number of common shares outstanding. Diluted earnings per share (EPS)
includes additional dilution from common stock equivalents, such as stock
issuable pursuant to the exercise of stock options and warrants. Common stock
equivalents were not included in the computation of diluted earnings per share
for the periods presented since the Company reported losses and to do so would
be anti-dilutive for periods presented.

Fair Value of Financial Instruments

      The carrying amounts reported in the balance sheet are considered by
management to be their estimated fair values for cash and cash equivalents,
accounts payable and accrued expenses because of the immediate or short-term
maturity of these financial instruments.

Stock-Based Compensation

      Currently employee stock awards under NanoSensors' compensation plans will
be accounted for in accordance with Accounting Principles Board Opinion No. 25
("APB 25"), "Accounting for Stock Issued to Employees", and related
interpretations. NanoSensors will provide the disclosure requirements of
Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation" ("SFAS 123"), and related interpretations. Stock-based awards to
non-employees are accounted for under the provisions of SFAS 123.

      NanoSensors will measure compensation expense for its employee stock-based
compensation using the intrinsic-value method. Under the intrinsic-value method
of accounting for stock-based compensation, when the exercise price of options
granted to employees is less than the estimated fair value of the underlying
stock on the date of grant, deferred compensation is recognized and is amortized
to compensation expense over the applicable vesting period.

      NanoSensors measures compensation expense for its non-employee stock-based
compensation under the Financial Accounting Standards Board (FASB) Emerging
Issues Task Force (EITF) Issue No. 96-18, "Accounting for Equity Instruments
that are Issued to Other Than Employees for Acquiring, or in Conjunction with
Selling, Goods or Services". The fair value of the option issued is used to
measure the transaction, as this is more reliable than the fair value of the
services received. The fair value is measured as the value of NanoSensors'
common stock on the date that the commitment for performance by the counterparty
has been reached or the counterparty's performance is complete. The fair value
of the equity instrument is charged directly to compensation expense and
additional paid-in capital.

Results of Operations for the Three Months Ended August 31, 2005 as Compared to
the Three Months Ended August 31, 2004.

      For the three months ended August 31, 2005 and for the three months ended
August 31, 2004, the Company had no sales. The Company is still in the
development stage. For the three months ended August 31, 2005, the Company
incurred total costs and expenses of $34,944, whereas for the three months ended
August 31, 2004, the Company recorded total costs and expenses of $144,663. The
76% reduction in total costs and expenses resulted from the Company being
without funds to implement its business plan.

      During the three months ended August 31, 2005, the Company incurred
general and administrative expenses of only $29,794, as it had minimal
operations, compared with $44,476 for the three month period ended August 31,
2004.

                                      -12-
<PAGE>

      Research and development expenses for the three months ended August 31,
2004 were $94,586, as compared with no research and development expenses in the
three months ended August 31, 2005. All research and development costs are
expensed as incurred. They are primarily incurred in connection with technology
development under a worldwide, perpetual, exclusive, marketing license entered
into on December 11, 2003, with Dr. Matthew Zuckerman, one of the Company's
founders and its Chief Scientist.

      Depreciation and amortization expense for both the three month period
ended August 31, 2005 and the three months ended August 31, 2004 was $5,150
primarily concerning office equipment and amortization of the license.

      Interest expense incurred for the three month period ended August 31, 2004
was $663 with no interest expense for the three month period ended August 31,
2005.

Results of Operations for the Nine Months Ended August 31, 2005 as Compared to
the Period from Inception (December 23, 2003) to August 31, 2004.

      For the nine months ended August 31, 2005 ("Period 2005") and for the
comparable period from inception (December 23, 2003) to August 31, 2004 ("Period
2004"), the Company had no sales. The Company is still in the development stage.
For Period 2005, the Company incurred total costs and expenses of $175,215,
whereas for Period 2004, the Company recorded total costs and expenses of
$525,085. The 67% reduction in total costs and expenses resulted from the
Company being without funds to implement its business plan.

      General and administrative expenses for Period 2005 were $57,981, as
compared with $112,520 for Period 2004. These expenses consist primarily of
professional fees as a result of raising money through private placements and
filings with the SEC, and consulting fees and rent.

      Research and development expenses for Period 2005 were $101,788, as
compared with $392,092 in Period 2004. All research and development costs are
expensed as incurred. They are primarily incurred in connection with technology
development under a worldwide, perpetual, exclusive, marketing license entered
into on December 11, 2003, with Dr. Matthew Zuckerman, one of the Company's
founders and its Chief Scientist.

      Depreciation and amortization expense for both the Period 2005 and Period
2004 was $15,450, primarily concerning office equipment and amortization of the
license.

      Interest expense incurred for Period 2004 was $5,691 with no interest
expense for Period 2005. This resulted from: (a) $100,000 of 10% bridge notes
issued in February 2004 which were converted into equity in May 2004; and (b)
the issuance of an aggregate of $150,000 of promissory notes in December 2003
and January 2004 of which $120,000 was converted into equity in August 2004 and
the remaining $30,000 was repaid also in August 2004, as described below.

Liquidity and Capital Resources at August 31, 2005

      The Company does not have an operating line of credit from a financial
institution and consequently relied on financing from investors to support its
operations. As of August 31, 2005, the Company had no cash on hand, as compared
with $13,558 at November 30, 2004. The Company has been unable to continue to
operate without additional financing.

                                      -13-
<PAGE>

      In December 2003 and February 2004, the Company borrowed $80,000 and
$40,000, respectively, from one unaffiliated investor and an additional $30,000
in January 2004, from a second unaffiliated investor neither of whom are selling
shareholders or are otherwise affiliated with the Company. These loans are
evidenced by interest bearing promissory notes. The first note for $80,000 had
an original maturity date of January 20, 2005, although $30,000 plus $2,500 of
interest was due as of April 30, 2004. The entire $80,000 plus $2,500 of accrued
interest was converted into 412,500 shares of Common Stock subsequent to April
30, 2004. The second note for $40,000 matured on March 9, 2004. In August 2004,
this $40,000 note was converted into 207,500 shares of Common Stock. The lender
on these two notes received 200,000 shares of common stock and no warrants at
the time the loans were made and 100,000 shares in consideration of the
conversion, in addition to the actual shares of Common stock provided for upon
conversion. The third note for $30,000 bore interest at 10% per annum, matured
on April 21, 2004 and was repaid in August 2004. The lender received 75,000
shares of Common Stock and Warrants to purchase 75,000 shares of Common Stock,
exercisable at $.20 per share for three years and an unaffiliated party received
7,500 shares and warrants to purchase 7,500 shares on the above terms at the
time these loans were made. All loan proceeds were used for administrative
expenses and research and development expenditures.

      In February 2004, the Company borrowed $100,000 in the aggregate from two
private investors obtained through the Company's investment banker Meyers
Associates, L.P. ("Meyers"). Meyers received a 10% sales commission and a 3%
non-accountable expense allowance. Interest on each note (the "Bridge Notes")
accrued at a rate of 10% per annum. These notes matured on the earlier of (a)
August 15, 2004, (b) the completion of a private placement of at least $500,000,
or (c) an event of default. Payment of the Bridge Notes was guaranteed by the
Company's two founders. The investors each received five-year warrants to
purchase 50,000 shares of common stock exercisable at $.25 per share. The Bridge
Notes were converted into shares of common stock and Class A Warrants in the
Company's April 2004 Private Placement, described below.

      In April 2004, the Company entered into a Placement Agent Agreement with
an investment banking firm, Meyers Associates, L.P. to privately offer and sell
on a "best efforts" basis, $550,000 of its securities in a private offering the
"April 2004 Private Placement." The private placement of units each consisted of
one share of common stock and one Class A Warrant to purchase one share of
Common Stock for five years at $.30 per share. On April 26, 2004, NanoSensors
closed on the entire $550,000 of private placement units. This included the
exchange of ($100,000) of Bridge Notes for private placement units. In addition,
the placement agent received warrants to purchase 50% of the units sold in the
equity offering at the same offering price of $.20 per unit exercisable until
April 30, 2009. The $463,000 of net proceeds were used by NanoSensors for
technology and product development, marketing, business development and general
and administrative expenses. The bulk of the development work, to date, has been
on sensor technology development, including the development of the porous
silicon sensor to be installed into the working prototype of the
handheld-battery powered Model 10, as well as sensors to be used in NanoSensors
perimeter-line powered model 100.

      During Period 2005, the President and Chief Executive Officer of the
Company made advances to the Company in the aggregate amount of $7,100. These
advances are non-interest bearing and are payable upon demand.

      The accompanying financial statements have been prepared on a going
concern basis, which contemplates the realization of assets and the settlement
of liabilities and commitments in the normal course of business. The Company
recognized net losses of $175,215 and $525,085 for Period 2005 and Period 2004,
respectively. Our independent auditors have included an explanatory paragraph in
their audit opinion issued in connection with our financial statements as of and
for the period ended November 30, 2004, which states that our recurring losses
since inception raises substantial doubt about our ability to continue as a
going concern. See also Note 2 of Notes to Financial Statements included herein.

                                      -14-
<PAGE>

      Management believes that our current level of general and administrative
expenses and research and development expenditures are necessary to accomplish
the Company's business strategy, and to further decrease these activities might
jeopardize the Company's ability to carry out our business strategy. The Company
has curtailed its activities as of the date of this report until it is able to
obtain additional financing.

      The Company had a working capital deficit of $346,887 at August 31, 2005,
as compared with $217,122 at November 30, 2004. In August 2004, $120,000 of
current notes payable and accrued interest were converted into equity. We have
funded the business throughout the development stage primarily through equity
and convertible debt investments from accredited investors.

      To date, we have not invested in derivative securities or any other
financial instruments that involve a high level of complexity or risk. We plan
to invest any excess cash in investment grade interest bearing securities.

Plan of Operation

      The Company cannot meet its working capital requirements without
additional funding. Until October 2005, the Company had been unable to obtain
approval from the NASD Corporate Financing Department to conduct its selling
securityholders secondary offering (the "Secondary") as well as to have its
securities approved for listing on the OTC Bulletin Board. It is through the
Secondary, or other means of financing, all of which are dependent upon the
Company's securities being publicly traded, that the Company expects to commence
commercial operations. NanoSensors believes that the gross proceeds of the
Secondary, of approximately $1,537,500 if all of the Warrants offered are
exercised, together with funds planned to be generated from operations, will be
sufficient to support our operations over approximately the next 20 months. If
50% of the Warrants registered are exercised, the Company would receive gross
proceeds of $768,750 which would be sufficient to support our operations for
approximately 10 months. The Company would then take appropriate actions and
reduce its product offerings to match available funds. These estimates assume
that NanoSensors will be able to produce for sale its initial product, its
handheld battery powered Model 10. Management believes that once it commences
sales of its Model 10, it will generate adequate cash flow to provide liquidity
needed for NanoSensors to continue as a going concern. If it does not generate
cash from revenues and/or the exercise of Warrants, NanoSensors will need to
obtain short term loans and equity funding from other sources. We would need to
raise additional funds in order to produce other products currently in
development. While on the other hand, if our initial products Model 10 and Model
100 are produced and sold, we expect to need additional equity to support the
higher inventory and accounts receivable levels accompanying such sales.
NanoSensors would seek to raise additional funds through a private placement of
its services. The Company also intends to seek financing from U.S. government
agencies, such as the Department of Homeland Security and Defense Advanced
Research Projects Agency (DARPA). Management believes that contractors and
systems integrators to the government may be sources of funding in exchange for
obtaining marketing rights from the Company for these sensor technologies so
that other companies may bear the cost of product development, marketing,
manufacturing and sales. If additional funds are required earlier than
anticipated, there can be no assurance that we will be able to obtain such
funds, if at all, from financial institutions, the exercise of the Warrants, or
otherwise, on a basis deemed acceptable.

ITEM 3.  CONTROLS AND PROCEDURES

      Our chief executive officer and chief financial officer evaluated the
effectiveness of our disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended)
as of August 31, 2005 and, based on that evaluation, concluded that, as of
August 31, 2005, we had sufficient controls and procedures for recording,
processing, summarizing and reporting information that is required to be
disclosed in our reports under the Securities Exchange Act of 1934, as amended,
within the time periods specified in the SEC's rules and forms.

                                      -15-
<PAGE>

      There has not been any change in our internal control over financial
reporting during our quarter ended August 31, 2005 that has materially affected,
or is reasonably likely to materially affect, our internal control over
financial reporting.

                           PART II. OTHER INFORMATION


ITEM 1. LEGAL PROCEEDINGS.

        None

ITEM 2. CHANGES IN SECURITIES.

        None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

        None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

        None

ITEM 5. OTHER INFORMATION.

        None

















                                      -16-
<PAGE>

ITEM 6.  EXHIBITS


31.1  Certification of the Chief Executive Officer and Chief Financial Officer
      required by Rule 13a-14(a) or Rule 15d-14(a).

32.1  Certification of the Chief Executive Officer and Chief Financial Officer
      required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.






































                                      -17-
<PAGE>

                                   SIGNATURES

      In accordance with Section 13 and 15(d) of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, on this October 20, 2005.


                                    NanoSensors, Inc.

                                    /s/ Ted Wong
                                    -----------------------------------------
                                    Ted Wong
                                    President and Chief Executive Officer


      In accordance with the Exchange Act, this report has been signed below by
the following persons on behalf of the registrant and in the capacities as of
October 20, 2005.


                                    /s/ Ted Wong
                                    -----------------------------------------
                                    Ted Wong
                                    President, Chief Executive Officer, Chief
                                    Financial Officer and Sole Director


























                                      -18-